Objective: Infliximab improves patient quality of life and is effective to control Crohn's disease refractory to the standard treatment. It lacks real world Brazilian data demonstrating that this improvement in quality of life and disease control is related to decrease of resource use mainly due to hospitalization reduction in moderate and severe Crohn disease patients receiving infliximab Methods: Thirty one gastroenterologists from southeast Brazil prospectively evaluated all their Crohn's disease patients during two months. They used a structured questionnaire specifically developed to evaluate resource use by patients with Crohn's disease Results: A total of 118 patients with moderate and severe disease were evaluated during 2 months. The patients average age was 30 years and the mean body weight was 62kg. Fourteen patients were using infliximab. The comparison among infliximab patients and standard care patients showed that 60.6% of the standard care patients needed hospitalization and only 21.4% of the infliximab patients needed hospitalization (p=0.005). The main reason for hospitalization among the standard care patients was due to anal fistula, and among the infliximab patients, was due to anemia/hemorrhage. Conclusion: The use of infliximab in the management of moderate and severe Crohn's disease can be contributive to reduction of the need of hospitalization among these patients.